Prognosis of Non-small-cell Lung Cancer Patients With Lipid Metabolism Pathway Alternations to Immunotherapy

Immune checkpoint inhibitors (ICIs) significantly improve the survival of patients with non-small-cell lung cancer (NSCLC), but only some patients obtain clinical benefits. Predictive biomarkers for ICIs can accurately identify people who will benefit from immunotherapy. Lipid metabolism signaling p...

Descripción completa

Detalles Bibliográficos
Autores principales: Cheng, Tianli, Zhang, Jing, Liu, Danni, Lai, Guorong, Wen, Xiaoping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Genetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317604/
https://www.ncbi.nlm.nih.gov/pubmed/34335679
http://dx.doi.org/10.3389/fgene.2021.646362

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8317604/
https://www.ncbi.nlm.nih.gov/pubmed/34335679
http://dx.doi.org/10.3389/fgene.2021.646362

Ejemplares similares